Myeloma: Classification and risk assessment

Rafael Fonseca, Jorge Monge

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a heterogeneous disease for which several new treatments are available. Much has been learned about its biology over the past 15 years. We now understand that there are various subtypes of the disease, each one associated with different outcomes and clinical pathological features. While a detailed classification of the disease into at least seven or eight major subtypes is possible, a practical clinical approach classifies the disease into high-risk and not-high-risk MM. This classification has allowed for tailored approaches to therapy and treatment planning. Furthermore, the discussion of outcomes with patients should include risk stratification, as the prospects for survival are quite different depending on whether the patient has high-risk MM or not. The tools for measuring risk subcategory are widely available and now routinely employed in the clinic. The continued search for genetic abnormalities that underlie the biology of MM may allow for even better precision therapy in the future.

Original languageEnglish (US)
Pages (from-to)554-566
Number of pages13
JournalSeminars in Oncology
Volume40
Issue number5
DOIs
StatePublished - Oct 2013

Fingerprint

Multiple Myeloma
Therapeutics
Survival

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Myeloma : Classification and risk assessment. / Fonseca, Rafael; Monge, Jorge.

In: Seminars in Oncology, Vol. 40, No. 5, 10.2013, p. 554-566.

Research output: Contribution to journalArticle

Fonseca, Rafael ; Monge, Jorge. / Myeloma : Classification and risk assessment. In: Seminars in Oncology. 2013 ; Vol. 40, No. 5. pp. 554-566.
@article{af4b02e03e384a09a6b95c29fba5c07a,
title = "Myeloma: Classification and risk assessment",
abstract = "Multiple myeloma (MM) is a heterogeneous disease for which several new treatments are available. Much has been learned about its biology over the past 15 years. We now understand that there are various subtypes of the disease, each one associated with different outcomes and clinical pathological features. While a detailed classification of the disease into at least seven or eight major subtypes is possible, a practical clinical approach classifies the disease into high-risk and not-high-risk MM. This classification has allowed for tailored approaches to therapy and treatment planning. Furthermore, the discussion of outcomes with patients should include risk stratification, as the prospects for survival are quite different depending on whether the patient has high-risk MM or not. The tools for measuring risk subcategory are widely available and now routinely employed in the clinic. The continued search for genetic abnormalities that underlie the biology of MM may allow for even better precision therapy in the future.",
author = "Rafael Fonseca and Jorge Monge",
year = "2013",
month = "10",
doi = "10.1053/j.seminoncol.2013.07.002",
language = "English (US)",
volume = "40",
pages = "554--566",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Myeloma

T2 - Classification and risk assessment

AU - Fonseca, Rafael

AU - Monge, Jorge

PY - 2013/10

Y1 - 2013/10

N2 - Multiple myeloma (MM) is a heterogeneous disease for which several new treatments are available. Much has been learned about its biology over the past 15 years. We now understand that there are various subtypes of the disease, each one associated with different outcomes and clinical pathological features. While a detailed classification of the disease into at least seven or eight major subtypes is possible, a practical clinical approach classifies the disease into high-risk and not-high-risk MM. This classification has allowed for tailored approaches to therapy and treatment planning. Furthermore, the discussion of outcomes with patients should include risk stratification, as the prospects for survival are quite different depending on whether the patient has high-risk MM or not. The tools for measuring risk subcategory are widely available and now routinely employed in the clinic. The continued search for genetic abnormalities that underlie the biology of MM may allow for even better precision therapy in the future.

AB - Multiple myeloma (MM) is a heterogeneous disease for which several new treatments are available. Much has been learned about its biology over the past 15 years. We now understand that there are various subtypes of the disease, each one associated with different outcomes and clinical pathological features. While a detailed classification of the disease into at least seven or eight major subtypes is possible, a practical clinical approach classifies the disease into high-risk and not-high-risk MM. This classification has allowed for tailored approaches to therapy and treatment planning. Furthermore, the discussion of outcomes with patients should include risk stratification, as the prospects for survival are quite different depending on whether the patient has high-risk MM or not. The tools for measuring risk subcategory are widely available and now routinely employed in the clinic. The continued search for genetic abnormalities that underlie the biology of MM may allow for even better precision therapy in the future.

UR - http://www.scopus.com/inward/record.url?scp=84886891720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886891720&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2013.07.002

DO - 10.1053/j.seminoncol.2013.07.002

M3 - Article

C2 - 24135400

AN - SCOPUS:84886891720

VL - 40

SP - 554

EP - 566

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5

ER -